Since Late 2021, Kuwait Has No AstraZeneca Doses Or Contract

British pharmaceutical giant AstraZeneca has made a significant announcement regarding its anti-COVID-19 vaccine, "Vaxifria." The vaccine, one of the earliest developed during the pandemic's onset, is being withdrawn from circulation, citing "commercial reasons" and an oversupply of updated vaccine doses.

Sources within the health sector reveal that the Ministry of Health in Kuwait has not acquired doses of the AstraZeneca vaccine since late 2021 due to the absence of a contract. Instead, the ministry's current vaccine inventory consists of other approved types that have been in use.

A spokesperson for AstraZeneca explained, "With the development of numerous COVID-19 vaccines targeting different variants, there is now an excess supply of updated vaccines available." This surplus has led to reduced demand for Vaxifria, prompting its discontinuation in manufacturing and supply.

The spokesperson added, "We are committed to collaborating with health authorities and partners to navigate the next steps and contribute significantly to the global fight against the COVID-19 pandemic."

AstraZeneca has commenced the process of withdrawing Vaxifria from markets across Europe, the Middle East, and Africa. This decision marks a significant shift in the landscape of COVID-19 vaccination efforts, sparking discussions on the future direction of vaccine distribution and deployment strategies.

Comments Post Comment

Leave a Comment

Submit